Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial. (nature.com)

Authors: Sun L … Wen PY Journal: Nature Communications Published: 2026-09-05 DOI: https://doi.org/10.1038/s41467-026-77433-z